| Market Cap | 171.15M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -104.19M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -2.00% |
| Sales | 19.27M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -12.00% |
| Dividend | N/A | Price/Book | 3.56 | EPS next 5Y | - | 52W High Chg | -67.00% |
| Recommedations | - | Quick Ratio | - | Shares Outstanding | 52.36M | 52W Low Chg | 73.00% |
| Insider Own | - | ROA | - | Shares Float | 15.49M | Beta | 1.01 |
| Inst Own | 9.24% | ROE | - | Shares Shorted/Prior | 128.98K/129.50K | Price | 3.85 |
| Gross Margin | 94.72% | Profit Margin | - | Avg. Volume | 154,414 | Target Price | - |
| Oper. Margin | -1,911.08% | Earnings Date | Sep 25 | Volume | 20,224 | Change | -5.64% |
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.
| HC Wainwright & Co. | Buy | Sep 26, 24 |
| Stifel | Buy | Sep 26, 24 |
| Canaccord Genuity | Buy | Apr 8, 24 |
| HC Wainwright & Co. | Buy | Apr 1, 24 |
| HC Wainwright & Co. | Buy | Mar 20, 24 |
| HC Wainwright & Co. | Buy | Mar 8, 24 |
| Stifel | Buy | Feb 16, 24 |
| HC Wainwright & Co. | Buy | Dec 21, 23 |
| Canaccord Genuity | Buy | Oct 27, 23 |